Mereo BioPharma Group plc
For the period ended Dec 31, 2024. Filed Mar 26, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 26, 2025
MREO$0.30+0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated statements of operations and comprehensive loss
| Year Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Revenue | $— | $10,000 |
| Operating expenses: | ||
| Cost of revenue | — | (2,574) |
| Research and development | (20,930) | (17,418) |
| General and administrative | (26,434) | (18,424) |
| Loss from operations | (47,364) | (28,416) |
| Other income/(expenses) | ||
| Interest income | 3,041 | 2,131 |
| Interest expense | (1,370) | (2,881) |
| Changes in the fair value of warrants | (419) | 245 |
| Foreign currency transaction gain/(loss), net | 1,210 | (2,347) |
| Other expenses, net | — | (10) |
| Benefit from research and development tax credit | 1,649 | 1,280 |
| Net loss before income tax | (43,253) | (29,998) |
| Income tax benefit | — | 532 |
| Net loss | $(43,253) | $(29,466) |
| Loss per share – basic and diluted | $(0.06) | $(0.04) |
| Weighted average shares outstanding – basic and diluted | 739,624,264 | 659,453,921 |
| Net loss | $(43,253) | $(29,466) |
| Other comprehensive (loss)/income – Foreign currency translation adjustments, net of tax | (1,364) | 4,202 |
| Total comprehensive loss | $(44,617) | $(25,264) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.